BioSpace News Archive

Abbott announced late-breaking data for MitraClip™, the leading therapy to treat leaky valves in people with mitral regurgitation, that demonstrate long-term benefits of the device in patients battling heart failure.

Amarin Corporation plc announced a new analysis from the VASCEPA/VAZKEPA cardiovascular outcomes REDUCE-IT study showing the effectiveness of VASCEPA®/VAZKEPA® in patients with recent acute coronary syndrome.

egnite, Inc., a leading digital health company for cardiovascular care, announces two novel research studies were presented at the American College of Cardiology’s 72nd Annual Scientific Session Together with the World Congress of Cardiology on March 5, 2023.

Immuneering Corporation announced that it will be presenting preclinical data on its lead program IMM-1-104 at the American Association for Cancer Research special conference targeting RAS, held March 5-8, 2023, in Philadelphia.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefits of the XARELTO® vascular dose over standard of care, demonstrating consistent benefit at 30 days, 90 days and up to three years following LER in patients with PAD.

An automated system that flags which patients could most benefit from an underused yet life-saving cardiology drug more than doubled new prescriptions, according to a pilot program test by researchers at NYU Grossman School of Medicine.

Adagene Inc., a company transforming the discovery and development of antibody-based therapies, announced the appointment of Professor Aurélien Marabelle, MD, PhD, to its Scientific and Strategic Advisory Board.

Lumos Pharma, Inc. announced that additional data from its OraGrowtH212 trial was included in an oral presentation of interim results at the 2023 International Meeting of Pediatric Endocrinology, held in Buenos Aires, Argentina, March 4-7, 2023.

BioArctic AB’s partner Eisai announced that the U.S. Food and Drug Administration has accepted Eisai’s supplemental Biologics License Application for LEQEMBI™ 100 mg/mL injection for intravenous use, supporting the conversion of the accelerated approval of LEQEMBI to a traditional approval.

Eisai Co., Ltd. and Biogen Inc. announced that the U.S. Food and Drug Administration has accepted Eisai’s supplemental Biologics License Application for LEQEMBI™ 100 mg/mL injection for intravenous use, supporting the conversion of the accelerated approval of LEQEMBI to a traditional approval.